Literature DB >> 19515627

Myocardial bridging in Taiwan: depiction by multidetector computed tomography coronary angiography.

Yu-Dong Chen1, Mei-Han Wu, Ming-Huei Sheu, Cheng-Yen Chang.   

Abstract

BACKGROUND/
PURPOSE: Myocardial bridging (MB) is a condition in which a segment of the major epicardial coronary artery is tunneled within and surrounded by the myocardium. This condition has been linked to severe complications. The aim of this study was to evaluate the incidence of MB in Taiwanese subjects examined with electrocardiogram-gated, 16-slice, multidetector computed tomography (MDCT) coronary angiography, as well as to determine the location, depth, and length of the bridged segments and the concomitant atherosclerosis of MB.
METHODS: From August 2004 to May 2005, 276 consecutive subjects referred to our department for MDCT coronary angiography were enrolled in the study after written informed consent was obtained from each participant.
RESULTS: Twenty-four subjects (8.7%) had at least one coronary segment that was completely surrounded by myocardium. Patients ranged in age from 27 to 76 years, with an average of 54 +/- 12 years. Thirty coronary segments were found to have MB. The most common location of MB was in segment 7, which accounted for 14 coronary segments (46.7%) of the total number of bridged segments; left anterior descending artery (LAD) segments accounted for 23 (76.7%); and right coronary artery and left circumflex artery segments accounted for three (10%) and two (6.7%), respectively. The length of bridged segments ranged from 5.2 to 50.6 mm, with an average length of 24.6 +/- 11.8 mm, and the depth of the bridged segments ranged from 0.5 to 9.1 mm, with an average depth of 3.65 +/- 1.89 mm. Two bridged segments (6.7%) had concomitant atherosclerosis; these were located in segment 7 (24.0 mm long and 6.10 mm deep) and segment 8 (27.1 mm long and 7.0 mm deep). Bridged segments with concomitant atherosclerosis were deeper, but not longer, compared with bridged segments without concomitant atherosclerosis (p < 0.05).
CONCLUSION: Electrocardiogram-gated MDCT is an effective noninvasive tool for evaluating MB in a clinical setting. The most common location of MB was in the LAD, especially in segment 7. Bridged segments with concomitant atherosclerosis were deeper, but not longer, compared with bridged segments without concomitant atherosclerosis.

Entities:  

Mesh:

Year:  2009        PMID: 19515627     DOI: 10.1016/S0929-6646(09)60094-2

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

1.  Prevalence and predictors of bridging of coronary arteries in a large Indonesian population, as detected by 64-slice computed tomography scan.

Authors:  J Wirianta; M Mouden; J P Ottervanger; J R Timmer; Y B Juwana; M-J de Boer; H Suryapranata
Journal:  Neth Heart J       Date:  2012-10       Impact factor: 2.380

2.  Myocardial bridging of the left anterior descending coronary artery: depiction rate and morphologic features by dual-source CT coronary angiography.

Authors:  Jin Ho Hwang; Sung Min Ko; Hong Gee Roh; Meong Gun Song; Je Kyoun Shin; Hyun Kun Chee; Joon Suk Kim
Journal:  Korean J Radiol       Date:  2010-08-27       Impact factor: 3.500

3.  Myocardial bridging analysis by coronary computed tomographic angiography in a Saudi population.

Authors:  Ragab Hani Donkol; Zizi Saad
Journal:  World J Cardiol       Date:  2013-11-26

4.  Evaluation of the morphological and clinical features of left anterior descending myocardial bridging with multi-detector computed tomography.

Authors:  Neşat Çullu; İbrahim Önder Yeniçeri; Murat Yunus Özdemir; İlknur Altun; Emrah Doğan
Journal:  Kardiochir Torakochirurgia Pol       Date:  2021-07-05

5.  Clinical value of the correlations of mural coronary artery compression extent with myocardial bridge length and thickness evaluated by 128-slice CT.

Authors:  Yu-Jun Niu; Xiang-Lin Zhang; A-Dan Cao; Bing Leng
Journal:  Exp Ther Med       Date:  2012-12-28       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.